The medical linear particle accelerator market size has grown strongly in recent years. It will grow from $2.68 billion in 2025 to $2.83 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to increasing global cancer prevalence, adoption of radiotherapy as a standard cancer treatment, expansion of oncology treatment centers, technological improvements in radiation delivery, rising healthcare infrastructure investments.
The medical linear particle accelerator market size is expected to see strong growth in the next few years. It will grow to $3.44 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing demand for minimally invasive cancer treatments, increasing focus on personalized oncology care, expansion of advanced radiotherapy facilities, rising awareness of early cancer treatment benefits, continuous innovation in radiation therapy equipment. Major trends in the forecast period include rising adoption of precision radiation therapy systems, growing demand for advanced tumor targeting techniques, increased integration of image-guided treatment capabilities, expansion of stereotactic and high-dose radiation therapies, higher focus on treatment accuracy and patient safety.
The increasing incidence of cancer is expected to drive the growth of the medical linear particle accelerator market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells, which can form tumors or spread to other parts of the body. The rise in cancer cases can be linked to factors such as environmental exposures, genetic predisposition, improved detection and screening, infections, hormonal influences, and greater awareness. Medical linear particle accelerators (LINACs) assist in cancer treatment by delivering precise high-energy radiation to target and eliminate cancer cells, improving treatment outcomes while minimizing side effects. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that the number of cancer cases diagnosed in the country increased from 160,570 in 2022 to 164,694 in 2023, representing a significant year-over-year rise. Consequently, the growing incidence of cancer is contributing to the expansion of the medical linear particle accelerator market.
Major companies in the medical linear particle accelerator market are concentrating on developing advanced technological solutions, such as radiotherapy systems, to improve treatment accuracy and enhance patient outcomes in cancer therapy. Radiotherapy systems are medical technologies, including linear accelerators, that deliver high-energy radiation to accurately target and treat tumors while minimizing harm to surrounding healthy tissue. For example, in May 2024, Elekta AB, a Sweden-based medical equipment company, introduced Elekta Evo, an AI-powered adaptive CT-linear accelerator designed to transform cancer care. Featuring Iris, a high-definition AI-enhanced imaging system, Elekta Evo allows clinicians to visualize treatment areas with exceptional clarity, ensuring precise tumor targeting while safeguarding healthy tissue. The system also includes adaptive radiation therapy capabilities, enabling both online and offline modifications to treatment plans, thereby personalizing care to the specific needs of each patient.
In June 2024, Leo Cancer Care Inc., a UK-based medical technology company specializing in cancer treatment systems, collaborated with TibaRay Inc. to develop a next-generation upright linear accelerator. This collaboration marks a significant advancement in radiation therapy by combining TibaRay's cutting-edge linear accelerator technology with Leo Cancer Care's innovative upright patient positioning and imaging system. The integrated solution is designed to provide more efficient and patient-centered cancer treatments. TibaRay Inc. is a US-based medical equipment manufacturer of next-generation particle-accelerator systems for cancer treatment.
Major companies operating in the medical linear particle accelerator market are Mitsubishi Electric Corporation, Siemens Healthineers AG, Toshiba Medical Systems Corporation, GE Healthcare, Shinva Medical Instrument Co Ltd, Sumitomo Heavy Industries Ltd, Neusoft Medical Systems Co Ltd, Elekta AB, Varex Imaging Corporation, Altair Engineering Inc, Accuray Incorporated, Brainlab, Nordion Inc., Ion Beam Applications S.A. (IBA), Hitachi Medical Corporation, ViewRay Technologies Inc., Laird Thermal Systems Inc., Panacea Medical Technologies Pvt Ltd, RadSource Technologies Inc., Xstrahl Limited, MedicalExpo S.A, ProTom International Inc., ASG superconductors, Galbino Technology Inc., Mevex Corporation, TibaRay Inc.
North America was the largest region in the medical linear particle accelerator market in 2025. The regions covered in the medical linear particle accelerator market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical linear particle accelerator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs influence the medical linear particle accelerator market by raising costs of imported precision components, electronic systems, and high-energy accelerator parts. Hospitals and radiotherapy centers in north america, europe, and asia-pacific are most affected due to reliance on advanced international suppliers. Increased tariffs can delay equipment upgrades and new installations. However, they also encourage local manufacturing, regional sourcing, and long-term supply chain resilience.
The medical linear particle accelerator market research report is one of a series of new reports that provides medical linear particle accelerator market statistics, including medical linear particle accelerator industry global market size, regional shares, competitors with a medical linear particle accelerator market share, detailed medical linear particle accelerator market segments, market trends and opportunities, and any further data you may need to thrive in the medical linear particle accelerator industry. This medical linear particle accelerator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A medical linear particle accelerator (LINAC) is a device utilized in radiation therapy to treat cancer by delivering high-energy X-rays or electron beams directly to tumors with precision, while minimizing exposure to surrounding healthy tissue. It accelerates electrons through microwave technology, generating radiation beams that conform to the shape of the tumor for effective treatment.
The primary types of medical linear particle accelerator products are dedicated linear accelerators and non-dedicated linear accelerators. A dedicated linear accelerator (linac) is a medical device specifically engineered to provide precise radiation therapy for cancer treatment while reducing harm to surrounding healthy tissue. It accommodates various treatment modalities, including intensity-modulated radiation therapy, volumetric modulated arc therapy, image-guided radiation therapy, stereotactic radiosurgery, and stereotactic body radiotherapy, serving a wide range of end users such as hospitals, radiology centers, clinics, and other healthcare facilities.
The medical linear particle accelerator market consists of sales of quality assurance (QA) tools, treatment accessories, multileaf collimators (MLCs), patient immobilization systems, and beam-shaping devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The medical linear particle accelerator market size is expected to see strong growth in the next few years. It will grow to $3.44 billion in 2030 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to growing demand for minimally invasive cancer treatments, increasing focus on personalized oncology care, expansion of advanced radiotherapy facilities, rising awareness of early cancer treatment benefits, continuous innovation in radiation therapy equipment. Major trends in the forecast period include rising adoption of precision radiation therapy systems, growing demand for advanced tumor targeting techniques, increased integration of image-guided treatment capabilities, expansion of stereotactic and high-dose radiation therapies, higher focus on treatment accuracy and patient safety.
The increasing incidence of cancer is expected to drive the growth of the medical linear particle accelerator market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells, which can form tumors or spread to other parts of the body. The rise in cancer cases can be linked to factors such as environmental exposures, genetic predisposition, improved detection and screening, infections, hormonal influences, and greater awareness. Medical linear particle accelerators (LINACs) assist in cancer treatment by delivering precise high-energy radiation to target and eliminate cancer cells, improving treatment outcomes while minimizing side effects. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that the number of cancer cases diagnosed in the country increased from 160,570 in 2022 to 164,694 in 2023, representing a significant year-over-year rise. Consequently, the growing incidence of cancer is contributing to the expansion of the medical linear particle accelerator market.
Major companies in the medical linear particle accelerator market are concentrating on developing advanced technological solutions, such as radiotherapy systems, to improve treatment accuracy and enhance patient outcomes in cancer therapy. Radiotherapy systems are medical technologies, including linear accelerators, that deliver high-energy radiation to accurately target and treat tumors while minimizing harm to surrounding healthy tissue. For example, in May 2024, Elekta AB, a Sweden-based medical equipment company, introduced Elekta Evo, an AI-powered adaptive CT-linear accelerator designed to transform cancer care. Featuring Iris, a high-definition AI-enhanced imaging system, Elekta Evo allows clinicians to visualize treatment areas with exceptional clarity, ensuring precise tumor targeting while safeguarding healthy tissue. The system also includes adaptive radiation therapy capabilities, enabling both online and offline modifications to treatment plans, thereby personalizing care to the specific needs of each patient.
In June 2024, Leo Cancer Care Inc., a UK-based medical technology company specializing in cancer treatment systems, collaborated with TibaRay Inc. to develop a next-generation upright linear accelerator. This collaboration marks a significant advancement in radiation therapy by combining TibaRay's cutting-edge linear accelerator technology with Leo Cancer Care's innovative upright patient positioning and imaging system. The integrated solution is designed to provide more efficient and patient-centered cancer treatments. TibaRay Inc. is a US-based medical equipment manufacturer of next-generation particle-accelerator systems for cancer treatment.
Major companies operating in the medical linear particle accelerator market are Mitsubishi Electric Corporation, Siemens Healthineers AG, Toshiba Medical Systems Corporation, GE Healthcare, Shinva Medical Instrument Co Ltd, Sumitomo Heavy Industries Ltd, Neusoft Medical Systems Co Ltd, Elekta AB, Varex Imaging Corporation, Altair Engineering Inc, Accuray Incorporated, Brainlab, Nordion Inc., Ion Beam Applications S.A. (IBA), Hitachi Medical Corporation, ViewRay Technologies Inc., Laird Thermal Systems Inc., Panacea Medical Technologies Pvt Ltd, RadSource Technologies Inc., Xstrahl Limited, MedicalExpo S.A, ProTom International Inc., ASG superconductors, Galbino Technology Inc., Mevex Corporation, TibaRay Inc.
North America was the largest region in the medical linear particle accelerator market in 2025. The regions covered in the medical linear particle accelerator market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the medical linear particle accelerator market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs influence the medical linear particle accelerator market by raising costs of imported precision components, electronic systems, and high-energy accelerator parts. Hospitals and radiotherapy centers in north america, europe, and asia-pacific are most affected due to reliance on advanced international suppliers. Increased tariffs can delay equipment upgrades and new installations. However, they also encourage local manufacturing, regional sourcing, and long-term supply chain resilience.
The medical linear particle accelerator market research report is one of a series of new reports that provides medical linear particle accelerator market statistics, including medical linear particle accelerator industry global market size, regional shares, competitors with a medical linear particle accelerator market share, detailed medical linear particle accelerator market segments, market trends and opportunities, and any further data you may need to thrive in the medical linear particle accelerator industry. This medical linear particle accelerator market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A medical linear particle accelerator (LINAC) is a device utilized in radiation therapy to treat cancer by delivering high-energy X-rays or electron beams directly to tumors with precision, while minimizing exposure to surrounding healthy tissue. It accelerates electrons through microwave technology, generating radiation beams that conform to the shape of the tumor for effective treatment.
The primary types of medical linear particle accelerator products are dedicated linear accelerators and non-dedicated linear accelerators. A dedicated linear accelerator (linac) is a medical device specifically engineered to provide precise radiation therapy for cancer treatment while reducing harm to surrounding healthy tissue. It accommodates various treatment modalities, including intensity-modulated radiation therapy, volumetric modulated arc therapy, image-guided radiation therapy, stereotactic radiosurgery, and stereotactic body radiotherapy, serving a wide range of end users such as hospitals, radiology centers, clinics, and other healthcare facilities.
The medical linear particle accelerator market consists of sales of quality assurance (QA) tools, treatment accessories, multileaf collimators (MLCs), patient immobilization systems, and beam-shaping devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Medical Linear Particle Accelerator Market Characteristics
3. Medical Linear Particle Accelerator Market Supply Chain Analysis
4. Global Medical Linear Particle Accelerator Market Trends and Strategies
5. Medical Linear Particle Accelerator Market Analysis of End Use Industries
7. Global Medical Linear Particle Accelerator Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Medical Linear Particle Accelerator Total Addressable Market (TAM) Analysis for the Market
9. Medical Linear Particle Accelerator Market Segmentation
10. Medical Linear Particle Accelerator Market Regional and Country Analysis
11. Asia-Pacific Medical Linear Particle Accelerator Market
12. China Medical Linear Particle Accelerator Market
13. India Medical Linear Particle Accelerator Market
14. Japan Medical Linear Particle Accelerator Market
15. Australia Medical Linear Particle Accelerator Market
16. Indonesia Medical Linear Particle Accelerator Market
17. South Korea Medical Linear Particle Accelerator Market
18. Taiwan Medical Linear Particle Accelerator Market
19. South East Asia Medical Linear Particle Accelerator Market
20. Western Europe Medical Linear Particle Accelerator Market
21. UK Medical Linear Particle Accelerator Market
22. Germany Medical Linear Particle Accelerator Market
23. France Medical Linear Particle Accelerator Market
24. Italy Medical Linear Particle Accelerator Market
25. Spain Medical Linear Particle Accelerator Market
26. Eastern Europe Medical Linear Particle Accelerator Market
27. Russia Medical Linear Particle Accelerator Market
28. North America Medical Linear Particle Accelerator Market
29. USA Medical Linear Particle Accelerator Market
30. Canada Medical Linear Particle Accelerator Market
31. South America Medical Linear Particle Accelerator Market
32. Brazil Medical Linear Particle Accelerator Market
33. Middle East Medical Linear Particle Accelerator Market
34. Africa Medical Linear Particle Accelerator Market
36. Medical Linear Particle Accelerator Market Competitive Landscape and Company Profiles
37. Medical Linear Particle Accelerator Market Other Major and Innovative Companies
40. Medical Linear Particle Accelerator Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Medical Linear Particle Accelerator Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses medical linear particle accelerator market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for medical linear particle accelerator? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The medical linear particle accelerator market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Dedicated Linear Accelerator; Non-Dedicated Linear Accelerator2) By Treatment Type: Intensity Modulated Radiation Therapy; Volumetric Modulated Arc Therapy; Image Guided Radiation Therapy; Stereotactic Radiosurgery And Stereotactic Body Radiotherapy
3) By End-User: Hospital; Radiology; Clinics; Other End-Users
Subsegments:
1) By Dedicated Linear Accelerator: Radiation Therapy Linear Accelerators; Medical Linear Accelerators for Cancer Treatment; High-Energy Linear Accelerators2) By Non-Dedicated Linear Accelerator: General Purpose Linear Accelerators; Laboratory-Grade Non-Dedicated Linear Accelerators; Research And Development Linear Accelerators
Companies Mentioned: Mitsubishi Electric Corporation; Siemens Healthineers AG; Toshiba Medical Systems Corporation; GE Healthcare; Shinva Medical Instrument Co Ltd; Sumitomo Heavy Industries Ltd; Neusoft Medical Systems Co Ltd; Elekta AB; Varex Imaging Corporation; Altair Engineering Inc; Accuray Incorporated; Brainlab; Nordion Inc.; Ion Beam Applications S.A. (IBA); Hitachi Medical Corporation; ViewRay Technologies Inc.; Laird Thermal Systems Inc.; Panacea Medical Technologies Pvt Ltd; RadSource Technologies Inc.; Xstrahl Limited; MedicalExpo S.A; ProTom International Inc.; ASG superconductors; Galbino Technology Inc.; Mevex Corporation; TibaRay Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Medical Linear Particle Accelerator market report include:- Mitsubishi Electric Corporation
- Siemens Healthineers AG
- Toshiba Medical Systems Corporation
- GE Healthcare
- Shinva Medical Instrument Co Ltd
- Sumitomo Heavy Industries Ltd
- Neusoft Medical Systems Co Ltd
- Elekta AB
- Varex Imaging Corporation
- Altair Engineering Inc
- Accuray Incorporated
- Brainlab
- Nordion Inc.
- Ion Beam Applications S.A. (IBA)
- Hitachi Medical Corporation
- ViewRay Technologies Inc.
- Laird Thermal Systems Inc.
- Panacea Medical Technologies Pvt Ltd
- RadSource Technologies Inc.
- Xstrahl Limited
- MedicalExpo S.A
- ProTom International Inc.
- ASG superconductors
- Galbino Technology Inc.
- Mevex Corporation
- TibaRay Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.83 Billion |
| Forecasted Market Value ( USD | $ 3.44 Billion |
| Compound Annual Growth Rate | 5.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
